If you or a loved one were treated with Dupixent (dupilumab) and were diagnosed with Cutaneous T-Cell Lymphoma (CTCL), you may be eligible for compensation.
You should contact the Cochran Firm if you or a loved one:
- Used Dupixent for at least one month, and
- Were diagnosed with Cutaneous T-Cell Lymphoma (CTCL), including subtypes such as mycosis fungoides or Sézary syndrome
A CTCL diagnosis may have occurred before or after Dupixent use, as evidence suggests the drug may cause rapid disease progression in some patients.
About Dupixent
Dupixent (dupilumab) is an injectable prescription medication commonly used to treat conditions such as eczema and other inflammatory diseases. It works by targeting specific immune pathways that contribute to inflammation.
Recent findings, however, suggest that Dupixent may be associated with the development or accelerated progression of Cutaneous T-Cell Lymphoma in certain patients.
Potential Injuries and Disease Progression
In some cases, patients experienced noticeable changes after starting Dupixent, including:
- Worsening or rapidly changing skin rashes
- Enlarged lymph nodes
- Increased severity or spread of lesions
- Progression to a later stage of CTCL during or after Dupixent use
The timeline between Dupixent use and the onset or progression of symptoms is a critical factor in evaluating these cases.
Practicing Law, The Cochran Way
The Cochran Firm is a nationally recognized law firm with offices across the country and decades of experience handling complex personal injury, product liability, and mass tort cases. Our attorneys are committed to holding corporations accountable and fighting for justice on behalf of individuals and families harmed by dangerous drugs and medical products.
